hydroxyurea

FDA Drug Profile — Siklos

hydroxyurea is listed in the FDA National Drug Code directory with 2 NDC codes, marketed under brand name including Siklos. Available dosage form: tablet, film coated.

Drug details

Generic Name
hydroxyurea
Brand Names
Siklos
Application Number
NDA208843
Sponsor
Medunik
NDC Codes
2
Dosage Forms
TABLET, FILM COATED
Routes
ORAL
Active Ingredients
HYDROXYUREA

Indications and Usage

1 INDICATIONS AND USAGE Hydroxyurea capsules are indicated for the treatment of: • Resistant chronic myeloid leukemia. • Locally advanced squamous cell carcinomas of the head and neck (excluding the lip) in combination with chemoradiation. Hydroxyurea capsules are an antimetabolite indicated for the treatment of: • Resistant chronic myeloid leukemia. ( 1) • Locally advanced squamous cell carcinomas of the head and neck, (excluding lip) in combination with concurrent chemoradiation. ( 1 )

Sources: openFDA, FDA Data Dashboard, FDA.gov. Report a data issue: hello@regdatalab.com.